Charles River Announces Strategic Partnership with Cypre, Expanding 3D In Vitro Services for Cancer Immunotherapy and Targeted Therapy Drug Screening

Rhea-AI Summary

Charles River Laboratories (NYSE: CRL) has partnered with Cypre, Inc. to enhance its 3D in vitro testing services. The collaboration grants access to Cypre's Falcon-X™ platform, a 3D tumor model technology that replicates the tumor microenvironment for better therapeutic efficacy predictions. This addition bolsters Charles River's existing cancer assay portfolio, facilitating more effective testing of immunotherapies and targeted treatments using a robust database of over 700 tumor models. The aim is to address cancer immunotherapy resistance and advance drug development.

Positive

• Strategic partnership with Cypre enhances 3D in vitro testing capabilities.
• Access to Falcon-X™ platform improves predictive screening for immuno-oncology compounds.
• Expansion of cancer assay portfolio allows for better therapeutic efficacy assessments.

Negative

• None.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a strategic partnership with Cypre, Inc., a biotechnology company that is using 3D hydrogel technology to advance the understanding of the tumor microenvironment and predict therapeutic efficacy. The partnership will provide Charles River clients with access to Cypre’s proprietary 3D tumor model platform, Falcon-X™, which will expand Charles River’s 3D in vitro testing services to further optimize immuno-oncological approaches for its clients.

The Falcon-X™ 3D In Vitro Tumor Assay Platform is a high content analysis screening option for cancer immunotherapy and targeted therapy. Utilizing Cypre’s patented 3D hydrogel patterning technology, Symphony^® and VersaGel^®, and proprietary methods that synergize with the breadth and depth of Charles River’s tumor model collection, the platform recreates the tumor microenvironment and enables predictive screening of innovative immuno-oncology compounds. As a part of Charles River’s integrated tumor model service platform, including patient-derived xenografts (PDX), Falcon-X™ will provide human data that translates to the clinic and identifies the efficacy of specific immunotherapy and targeted therapeutic treatments for patients.

Charles River offers a range of cancer cell-based assays, including PDX assays and assays representing the entire tumor microenvironment (TME), so therapies are not only tested for their effect on real patient materials, but also their interaction with the human immune systems. Through this collaboration, Charles River will now have a critical new addition to our human oncology assay repertoire, allowing identification of therapeutics that overcome cancer immunotherapy resistance.

The partnership will also allow Cypre to screen multiple therapeutic modalities alone or in combination utilizing Charles River’s genomically annotated and in vivo characterized cancer model database. The database is comprised of more than 700 tumor models, including PDX, cell lines and cell line derived xenografts. These models have been extensively profiled for histological features, molecular data, and sensitivity to standard-of-care compounds, allowing a precise selection of suitable tumor models for preclinical anti-cancer agent testing. The biological advantages of PDX include the retention of histological and genetic characteristics of the donor tumor and the preservation of cell-autonomous heterogeneity, which increase the translational relevance of the Cypre platform significantly. The breadth and depth of Charles River’s cancer model database enable the offering of a clinically relevant tumor panel in Cypre’s innovative 3D platform, and the platform's compelling predictivity for in vivo PDX models allows streamlined programs and translation to the clinic.

Approved Quotes

• “Immunotherapy is a complex, yet promising area of development in cancer treatment. Cypre’s platform enables the ideal tumor culturing conditions for assaying various immunotherapies and targeted therapies and provides robust, reproducible data sets without compromising throughput that strongly correlates to our PDX in vivo results. By broadening our 3D in vitro services with this collaboration, we can provide our clients with a complete, integrated tumor model service platform.” – Birgit Girshick, Corporate Executive Vice President, Discovery and Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services, Charles River
• “Charles River is the premier CRO in discovery and early development services, and we are thrilled to partner with their team to drive a combined offering. Our Falcon-X™ platform provides Charles River customers with expanded access to patient-derived 3D in vitro screening services and a new way to assay the immune cell compartment within the tumor microenvironment. We look forward to building this relationship and providing more customers with our unique solution that will improve targeted and immuno-therapeutic options for cancer patients.” – Kolin Hribar, PhD, Founder and CEO, Cypre

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

About Cypre

Cypre has developed Falcon-X™, the 3D in vitro tumor model platform that assays targeted and immuno-therapy efficacy in the tumor microenvironment. We are now applying this approach with strategic partners for therapeutic discovery, lead validation, and precision medicine. To learn more about us, visit www.cypre.co.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210128005203/en/

FAQ

What is the new partnership between Charles River Laboratories and Cypre about?

Charles River Laboratories has partnered with Cypre to integrate the Falcon-X™ 3D tumor model platform into its services, improving its cancer testing capabilities.

How does the Falcon-X™ platform benefit Charles River's clients?

The Falcon-X™ platform provides clients with advanced predictive screening for immunotherapies and targeted treatments by replicating the tumor microenvironment.

What are the key features of the Falcon-X™ 3D tumor model platform?

The Falcon-X™ platform utilizes patented 3D hydrogel technology for high-content analysis in cancer research, offering predictive insights that correlate with in vivo results.

How many tumor models are included in Charles River's cancer model database?

Charles River's cancer model database includes over 700 tumor models, which have been extensively characterized for various research applications.

What is the significance of this partnership for cancer treatment development?

This partnership aims to improve the development of cancer treatments by providing comprehensive testing that addresses challenges in immunotherapy resistance.